Most women diagnosed in the early stages of breast cancer are likely to have a great prognosis. It is also likely that they remain disease free for several years after their treatment ends. However, the side effects of such treatments associated with bone issues are also likely to have an effect on the patient’s bone health in the long run. The bone loss associated with breast cancer therapy like endocrine therapy may contribute towards the risk of osteoporosis and bone fractures in the long run. In respect to treating such diseases in breast cancer cases, an intravenous bisphosphonate known as zoledronic acid is believed to play an important role.
